Biocryst Pharmaceuticals reported $49.62M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Alnylam Pharmaceuticals ALNY:US $ 190.3M 35.75M
Biocryst Pharmaceuticals BCRX:US $ 49.62M 36.44M
Chugai Pharma 4519:JP Y 153353M 39874M
Daiichi Sankyo 4568:JP Y 178917M 37069M
Gilead Sciences GILD:US $ 4827M 235M
GlaxoSmithKline GSK:LN 5.57B 566M
Glaxosmithkline GSK:US $ 5573M 566M
Intra Cellular Therapies ITCI:US $ 18.01M 3.58M
Karyopharm Therapeutics KPTI:US $ 21.46M 864K
Neurocrine Biosciences NBIX:US $ 285.8M 52.1M
Ptc Therapeutics PTCT:US $ 109.32M 0.48M
Regeneron Pharmaceuticals REGN:US $ 4444.8M 2224.1M
Sarepta Therapeutics SRPT:US $ 144.57M 19.99M
Ultragenyx Pharmaceutical RARE:US $ 83.84M 10.37M
Vertex Pharmaceuticals VRTX:US $ 1565.4M 33.42M
YTE INCY:US $ 673.08M 92.18M
Zogenix ZGNX:US $ 17.57M 4.56M